Company: SNY
Filing Date: 2025-10-27
Form Type: 424B5
Source: 0001193125-25-250786
Chunk: 68

Company: Sanofi
Filing Date: 2025-10-27
Form: 424B5
Chunk 68
---
 such terms are understood pursuant to the FinSA, and neither this prospectus supplement nor any other offering or marketing material relating to the notes
may be publicly distributed or otherwise made publicly available in Switzerland, except to any investor that qualifies as a professional client within the meaning of the FinSA.

Neither this prospectus supplement nor any other marketing or offering material relating to the notes has been or will be filed with, or
reviewed or approved by any Swiss review body, and none of this prospectus supplement or any other marketing or offering material relating to the notes complies with the disclosure requirements applicable to a prospectus within the meaning of the
FinSA.

Other Jurisdictions

In the Underwriting Agreement, each Underwriter severally represents, warrants and agrees that with respect to any other jurisdiction outside
the United States, neither it nor its affiliates nor anyone acting on its or their behalf has or have offered or sold and will not offer or sell any notes in any jurisdiction, except under circumstances that resulted or will result in compliance
with the applicable rules and regulations of such jurisdiction and in no case under circumstances that constitute or will constitute a public offering or otherwise require the filing of any documentation with any authority (market or otherwise) or
national securities exchange in any such jurisdiction.

S-49

VALIDITY OF THE NOTES

The validity of the notes offered hereby will be passed upon by Jones Day, French and U.S. counsel for Sanofi. Certain matters under the laws
of France and the United States will be passed upon for the underwriters by Clifford Clifford Chance Europe LLP and Clifford Chance LLP.

S-50

EXPERTS

The financial statements as of December 31, 2024 and for the year ended December 31, 2024 and management’s assessment of the
effectiveness of internal control over financial reporting (which is included in Management’s Report on Internal Control over Financial Reporting) as of December 31, 2024 incorporated in this prospectus supplement by reference to the
Annual Report on Form 20-F for the year ended December 31, 2024 have been so incorporated in reliance on the report of PricewaterhouseCoopers Audit and Forvis Mazars SA, independent registered public accounting firms, given on the
authority of said firms as experts in auditing and accounting.

The financial statements as of December 31, 2023 and 2022, and for
each of the two years in the period ended December 31, 2023 incorporated in this prospectus supplement by reference